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Long-chain 3-hydroxyacyl-coenzyme A dehy-
drogenase deficiency (LCHADD) is a rare inborn 
metabolic disease with the significant cardiac 
involvement, but remains without an established 
frequency of its occurrence. Its pathophysiology 
has not been fully understood or explained until 
now [1–3]. In the literature, there are sparse re-
ports about cardiac symptoms in LCHADD [4–7]. 
Inborn errors of metabolism could often present 
with cardiomyopathy as it does with other diseases 
such as mitochondrial and lysosomal storage [8, 9]. 
Seventeen children with LCHADD confirmed 
genetically at the average age of 6 months (range, 
0.1–13.0 years) were admitted and were under 
regular follow-up. They were all from 15 unrelated 
families in the Kashubian area of Poland (Table 1). 
Molecular analysis of gene coding for mitochondrial 
trifunctional protein revealed 1528G>C mutation 
of the HADHA gene (locus 2p23) in all of them. 
Two cases (patients 10, 11) were detected through 
newborn screening by tandem mass spectrometry. 
In the cases of two other children (patients 7, 8), 
the suspicion of LCHADD was established because 
of the positive family history. The other patients 
were diagnosed after the first episode of clini-
cal decompensation. Cardiac abnormalities were 
detected in 15 of 17 (88.2%) patients (Table 1). 
Cardiomyopathy was diagnosed in 11 (64.7%) 
children. In 2 cases (patients 9, 16), both types of 
cardiomyopathies, dilated cardiomyopathy (DCM) 
followed by hypertrophic cardiomyopathy, were 
disclosed in the follow-up period [5]. One initially 
healthy child (patient 11) with no echocardiographic 
evidence of any type of cardiomyopathy, developed 
an acute DCM and died a few hours later after 
the first symptoms of decompensation; DCM was 
confirmed by autopsy. Four children (patients 10, 
12, 14, 15), with detected DCM at the time of di-
agnosis of LCHADD, manifested the normalization 
of echocardiographic image during the follow-up. 
Seven other patients (patients 2, 4, 6, 7, 8, 11, 17) 
from this study group had no echocardiographical 
evidence of any type of cardiomyopathy up to their 
final follow-up visit at the end of the study.  The car-
diomyopathies were not the only cardiac anomalies 
observed in these patients. One child (patient 7) 
was diagnosed with intermittent ventricular preex-
citation on 24 h Holter-electrocardiography moni-
toring and one girl (patient 1) with prolongation of 
QTc. In the other 8 children (patients 2, 6, 8, 9, 12, 
14, 15, 16) unspecific repolarization abnormalities 
were identified during the follow-up period. Ad-
ditionally, in one child (patient 13) coarctation of 
the aorta was diagnosed. All children maintained 
a low-fat diet with medium-chain triglycerides 
(MCTs) supplementation (compliance 95–100%) 
and standard heart failure treatment if necessary. 
As it can be seen only 4 patients were diag-
nosed directly after screening or after positive 
family history (patients 7, 8, 10, 11). The remain-
101www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
2017, Vol. 24, No. 1, 101–104
DOI: 10.5603/CJ.2017.0009
Copyright © 2017 Via Medica
ISSN 1897–5593LETTER TO THE EDITOR
P
at
ie
nt
G
en
d
er
C
o
ur
se
 o
f 
p
re
gn
an
cy
G
A
B
ir
th
  
w
ei
gh
t 
[g
]
A
ge
 a
t 
 
d
ia
gn
o
si
s 
[y
ea
r]
A
ge
 o
f 
 
d
ea
th
  
[y
ea
r]
A
ut
o
p
sy
A
ct
ua
l  
ag
e 
 
[y
ea
r]
C
ar
d
io
m
yo
p
at
hy
C
ar
ni
ti
ne
 
in
ta
ke
E
C
G
 
N
G
E
C
H
O
A
ut
o
p
sy
1
F
N
o
rm
al
40
30
00
13
.7
1
–
–
29
.8
7
N
–
–
LQ
T
c
–
2
M
P
re
ec
la
m
p
si
a
36
*
22
00
0.
53
2.
59
N
A
*
D
C
M
N
A
Y
E
S
U
R
1
3
M
N
o
rm
al
38
*
31
00
2.
88
9.
37
D
C
M
 
*
D
C
M
D
C
M
 
–
N
E
–
4
M
N
o
rm
al
38
30
00
0.
07
–
–
14
.9
3
N
–
–
N
E
1
5
M
N
o
rm
al
39
*
31
00
0.
32
0.
64
D
C
M
*
D
C
M
D
C
M
–
N
E
1
6
F
N
o
rm
al
38
35
00
0.
37
–
–
14
.1
8
N
–
Y
E
S
U
R
1
7
M
N
o
rm
al
32
17
00
0.
08
 (F
H
)
–
–
11
.9
6
N
–
–
I–
W
P
W
1
8
M
N
o
rm
al
38
32
00
0.
06
 (F
H
)
–
–
12
.3
3
N
–
–
U
R
1
9
M
N
o
rm
al
33
13
50
0.
16
–
–
10
.3
5
D
C
M
/H
C
M
/N
–
–
U
R
1
10
M
N
o
rm
al
40
31
00
0.
08
 (N
B
S
+
)
–
–
9.
84
D
C
M
/N
–
Y
E
S
N
E
1
11
F
N
o
rm
al
37
*
27
00
1.
51
1.
64
D
C
M
*
N
D
C
M
–
N
E
–
12
M
N
o
rm
al
39
30
00
0.
8
–
–
9.
11
D
C
M
/N
–
Y
E
S
U
R
1
13
M
N
o
rm
al
37
*
30
00
0.
07
0.
48
D
C
M
*
N
A
D
C
M
–
N
A
–
14
F
N
o
rm
al
40
33
00
1.
18
–
–
8.
35
D
C
M
/N
–
–
U
R
–
15
F
T
w
ee
n 
 
p
re
gn
an
cy
35
20
00
0.
73
–
–
8.
01
D
C
M
/N
–
–
U
R
1
16
F
N
o
rm
al
40
32
00
0.
21
–
–
7.
4
D
C
M
/H
C
M
/N
–
–
U
R
1
17
M
N
o
rm
al
38
32
00
0.
03
 (N
B
S
+
)
–
–
3.
65
N
–
–
N
E
–
S
um
-
m
ar
y 
o
f 
th
e 
17
 
LC
H
A
D
D
 
p
at
ie
nt
s
6 
F/
 
/1
1 
M
1/
17
  
p
re
ec
la
m
p
si
a
1/
17
 tw
ee
n 
p
re
gn
an
cy
4/
17
  
p
re
te
rm
M
ed
ia
n:
 
30
00
R
an
ge
: 
13
50
–3
50
0
M
ed
ia
n:
 
0.
5
R
an
ge
: 
0.
1–
13
.0
5/
17
  
d
ea
th
s
 4
/5
 a
ut
o
p
si
es
 
co
nf
ir
m
at
io
n 
o
f D
C
M
M
ed
ia
n:
  
9.
02
R
an
ge
: 
 
0.
48
–2
9.
78
11
/1
7 
D
C
M
 
2 
tr
an
si
si
o
n 
 
D
C
M
/H
C
M
/N
 
4 
tr
an
si
si
o
n 
D
C
M
/N
5 
D
C
M
 fr
o
m
 th
e 
b
eg
in
in
g 
to
 th
e 
E
O
S
6/
17
 N
 fr
o
m
 th
e 
b
eg
in
in
g 
to
 th
e 
E
O
S
4/
17
  
ca
rn
iti
ne
  
in
ta
ke
6/
17
  
no
rm
al
8/
17
 U
R
1/
17
 L
Q
T
c
1/
17
  
I–
W
P
W
11
/1
7 
 
N
G    
 
 
 
 
 
 
 
 
 
*D
ea
th
; 
N
B
S
+
 —
 d
ia
gn
o
si
s 
th
ro
ug
h 
ne
w
b
o
rn
 s
cr
ee
ni
ng
; 
G
A
 —
 g
es
ta
tio
na
l a
ge
; 
M
 —
 m
al
e;
 F
 —
 fe
m
al
e;
 F
H
 —
  f
am
ily
 h
is
to
ry
; 
N
 —
 n
o
rm
al
 h
ea
rt
; 
N
A
 —
 n
o
n-
ap
lic
ab
le
; 
E
O
S
 —
 e
nd
 o
f s
tu
d
y 
(la
st
 fo
llo
w
-u
p
 
vi
si
t o
r 
d
ea
th
; 
LQ
T
c 
—
 lo
ng
 Q
T
c;
 N
E
 —
 n
o
rm
al
 E
C
G
 fo
r 
ag
e;
 U
R
 —
 u
ns
p
ec
ifi
c 
re
p
o
la
ri
za
tio
n 
ab
no
rm
al
iti
es
; 
I–
W
P
W
 —
 in
te
rm
itt
an
t W
o
lff
-P
ar
ki
ns
o
n-
W
hi
te
; 
N
G
 —
 n
as
o
ga
st
ri
c 
tu
b
e
C
ar
d
io
m
yo
p
at
hy
 ty
p
e:
 d
ila
te
d
 (D
C
M
);
 h
yp
er
tr
o
p
hi
c 
(H
C
M
)  
D
C
M
 —
 d
ila
te
d
 c
ar
d
io
m
yo
p
at
hy
 in
 p
at
ie
nt
s 
2,
 3
, 5
, 9
, 1
0,
 1
2,
 1
4,
 1
5,
 1
6 
is
 d
ef
in
ed
 a
s 
ej
ec
tio
n 
fr
ac
tio
n 
(E
F)
 <
 5
0%
  
D
C
M
/H
C
M
/N
 —
 d
ila
te
d
 c
ar
d
io
m
yo
p
at
hy
 a
t t
he
 d
ia
gn
o
si
s 
co
nv
er
te
d
 to
  h
yp
er
tr
o
p
hi
c 
ca
rd
io
m
yo
p
at
hy
 a
nd
 th
en
 to
 th
e 
no
rm
al
 h
ea
rt
 in
 fo
llo
w
–u
p
 in
 p
at
ie
nt
s 
9 
an
d
 1
6 
D
C
M
/N
 —
 d
ila
te
d
 c
ar
d
io
m
yo
p
at
hy
 a
t t
he
 d
ia
gn
o
si
s 
co
nv
er
te
d
 to
 th
e 
no
rm
al
 h
ea
rt
 in
 fo
llo
w
-u
p
 in
 p
at
ie
nt
s 
10
, 1
2,
 1
4,
 1
5
102 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 1
ing patients had the diagnosis established after 
clinical decompensation. Therefore, only in 4 cases 
(patients 7, 8, 10, 11) the restriction of fat and 
MCTs supplementation were included initially 
with 10–20% of energy as MCTs and limited long-
-chain fatty acids intake (10% of total energy). 
In the remaining patients, the dietary restriction 
was included after diagnosis confirmation [2]. In 
the infantile period nasogastric tube feeding was 
frequently used but none were fed via percutane-
ous endoscopic gastrostomy [3]. Only children 
with documented l-carnitine deficiency received 
l-carnitine supplementation (5 out of 17) in doses 
varying from 5 to 100 mg/kg/day intermittently. 
Five (28%) patients died during follow-up. 
There were 3 (patients 2, 5, 13) hospital deaths. 
The cause of death was the metabolic crisis (trig-
gered by an infection) with a rapid progression 
of heart failure. It should be emphasized that the 
other 2 patients (patients 5, 11) demonstrated 
normal echocardiography before metabolic de-
compensation, with a sudden development of 
cardiomyopathy, which was the direct reason for 
the death at home. In both cases, an autopsy was 
performed and revealed dilatation of the left heart 
and histological evidence of DCM. 
Living patients age ranged from 3.5 to 29.8 
years and follow-up from 3.4 to 16.8 years (me-
dian 9.02 years). They remained on treatment and 
were intermittent symptomatic with an accidental 
increase of creatinine kinase (CK) levels with no 
echocardiographic and/or electrocardiographic 
abnormalities parallel to CK increase. Three of 
these (patients 4, 10, 15) demonstrated episodes 
of rhabdomyolysis parallel to extremely high 
CK, but without any echocardiographic and/or 
electrocardiographic abnormalities. We noticed 
that even with restricting diet most incidents of 
decompensation proceeded subsequently, even 
with a short-lived drop in calorie of meals rather 
than meal composition. 
In LCHADD, the metabolism of hydroxy-long-
chain fatty acids is disturbed. The clinical manifes-
tation depends both on toxicity of hydroxy-long-
-chain fatty acids esters (which in a cardiac muscle, 
with myocytes damage, leads to cardiomyopathy 
and heart arrhythmias) as well as energy produc-
tion disorder — too small amount of adenosine 
triphosphate in proportion to energetic needs of 
cells is produced. The concept assumes that during 
fasting, the main source of energy production for 
some tissues, including cardiac muscles, are ketone 
bodies produced via fatty acid beta-oxidation. This 
source was not available in LCHADD. The fatal 
effect of lowering the cellular pH [9, 10] should 
also be considered.
One of the largest studies of patients with the 
LCHADD was done by den Boer et al. [11]. That 
study dated from 2002, had a cohort of 50 patients 
and 42% had cardiomyopathies. In other studies 
which were conducted in patients diagnosed with 
LCHADD, the frequency of cardiomyopathies was 
variable. In another large study of fatty acid oxidation 
disorders, described 107 patients [12], in 28 (26.2%) 
cases cardiomyopathies were also reported.
Rarely are the cardiac arrhythmias reported 
in LCHADD [7], probably because of the sudden 
death which usually occurs at home with no pos-
sibility to monitor the heart rate. 
The diagnosis of LCHADD in the presented 
cohort of children was usually established during 
the first months of life because of the child’s de-
teriorating health status. Over the last few years, 
the Tandem-MS screening and the genetic confir-
mation of the disease have rapidly improved early 
diagnosis. In general, the recurrent episodes of 
hypoglycemia, as a consequence of even a short, 
low caloric intake causes a wide spectrum of cardiac 
symptoms [5].
Although the cardiomyopathy is not the pri-
mary finding in the LCHADD, it can be diagnosed 
by echocardiography. The electrocardiographic 
and echocardiographic examinations should be 
done in every child both with diagnosis of, or with 
suspicion of LCHADD. At this center, the current 
cardiological practice is to follow-up these pa-
tients regularly at 6–12 month intervals at the out-
patient clinic as recommended by Spiekerkoetter 
et al. [1]. Such a practice can prevent further car-
diac complications which is also equally important 
in the perspective of decompensation process and 
cardiac death. It is possible that the magnetic 
resonance images of the heart in these patients 
when their echocardiography images are normal 
will play a significant role in our understanding 
of this phenomenon. Further basic research and 
multicenter clinical trials are required in order to 
understand this better.
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